Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Feb;117(3):455–462. doi: 10.1111/j.1476-5381.1996.tb15212.x

Characterization of the endothelin receptor selective agonist, BQ3020 and antagonists BQ123, FR139317, BQ788, 50235, Ro462005 and bosentan in the heart.

M G Peter 1, A P Davenport 1
PMCID: PMC1909322  PMID: 8821534

Abstract

1. In this study we used ligand binding techniques to determine the affinity and selectivity of endothelin receptor agonists and antagonists in human left ventricle which expresses both ETA and ETB receptors, and compared these results with cardiovascular tissues from rat and porcine hearts. 2. The linear tripeptide antagonist, FR139317 competed for [125I]-ET-1 binding to human left ventricle with over 200,000 fold selectivity for the ETA receptor (KD ETA = 1.20 +/- 0.28 nM, KDETB = 287 +/- 93 microM). The ETA-selective non-peptide antagonist, 50235, competed with lower affinity and selectivity (KDETA = 162 +/- 61 nM, KDETB = 171 +/- 42 microM) in this tissue. BQ123 and FR139317 also showed high selectivity (greater than 20,000 fold) and affinity in rat (BQ123: KDETA = 1.18 +/- 0.16 nM, KDETB = 1370 +/- 1150 microM; FR139317: KDETA = 2.28 +/- 0.30 nM, KDETB = 292 +/- 114 microM) and pig heart (BQ123: KDETA = 0.52 +/- 0.05 nM, KDETB = 70.4 +/- 4.0 microM; FR139317: KDETA = 2.17 +/- 0.51 nM, KDETB = 47.1 +/- 5.7 microM) (n > or = 3 individuals +/- s.e.mean). 3. Although BQ3020 competed with over 1000 fold selectivity for the ETB subtype in human heart (KDETB = 1.38 +/- 0.72 nM, KDETA = 2.04 +/- 0.21 microM) the peptide inhibited only the binding of [125I]-ET-1 at concentrations greater than 100 nM in rat and porcine heart. This is in contrast to the data from the ETA-selective antagonists which indicated the presence of ETB sites in these tissues from animal hearts. 4. The peptide antagonist, BQ788, had a low, micromolar affinity (KD = 1.98 +/- 0.13 microM) using human left ventricle and no significant selectivity for the human ETB-subtype in this tissue. 5. The non-peptide ET antagonists, Ro462005 (KD = 50.3 +/- 9.5 microM) and bosentan (Ro470203; KD = 77.9 +/- 7.9 nM) competed monophasically for [125I]-ET-1 binding sites in human left ventricle. 6. The results show that the ETA antagonists, BQ123 and FR139317, are highly selective for ETA receptors in all cardiac tissues tested, whereas BQ788 has a low affinity and no selectivity in this human tissue. Further we showed that there are species differences in the binding of BQ3020 to the ETB receptors in the hearts derived from human, rat and pig.

Full text

PDF
455

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adachi M., Yang Y. Y., Furuichi Y., Miyamoto C. Cloning and characterization of cDNA encoding human A-type endothelin receptor. Biochem Biophys Res Commun. 1991 Nov 14;180(3):1265–1272. doi: 10.1016/s0006-291x(05)81332-4. [DOI] [PubMed] [Google Scholar]
  2. Arai H., Nakao K., Takaya K., Hosoda K., Ogawa Y., Nakanishi S., Imura H. The human endothelin-B receptor gene. Structural organization and chromosomal assignment. J Biol Chem. 1993 Feb 15;268(5):3463–3470. [PubMed] [Google Scholar]
  3. Aramori I., Nirei H., Shoubo M., Sogabe K., Nakamura K., Kojo H., Notsu Y., Ono T., Nakanishi S. Subtype selectivity of a novel endothelin antagonist, FR139317, for the two endothelin receptors in transfected Chinese hamster ovary cells. Mol Pharmacol. 1993 Feb;43(2):127–131. [PubMed] [Google Scholar]
  4. Bax W. A., Bruinvels A. T., van Suylen R. J., Saxena P. R., Hoyer D. Endothelin receptors in the human coronary artery, ventricle and atrium. A quantitative autoradiographic analysis. Naunyn Schmiedebergs Arch Pharmacol. 1993 Oct;348(4):403–410. doi: 10.1007/BF00171340. [DOI] [PubMed] [Google Scholar]
  5. Bolger G. T., Liard F., Krogsrud R., Thibeault D., Jaramillo J. Tissue specificity of endothelin binding sites. J Cardiovasc Pharmacol. 1990 Sep;16(3):367–375. doi: 10.1097/00005344-199009000-00004. [DOI] [PubMed] [Google Scholar]
  6. Clozel M., Breu V., Burri K., Cassal J. M., Fischli W., Gray G. A., Hirth G., Löffler B. M., Müller M., Neidhart W. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature. 1993 Oct 21;365(6448):759–761. doi: 10.1038/365759a0. [DOI] [PubMed] [Google Scholar]
  7. Clozel M., Breu V., Gray G. A., Kalina B., Löffler B. M., Burri K., Cassal J. M., Hirth G., Müller M., Neidhart W. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther. 1994 Jul;270(1):228–235. [PubMed] [Google Scholar]
  8. Davenport A. P., Maguire J. J. Is endothelin-induced vasoconstriction mediated only by ETA receptors in humans? Trends Pharmacol Sci. 1994 Jan;15(1):9–11. doi: 10.1016/0165-6147(94)90120-1. [DOI] [PubMed] [Google Scholar]
  9. Davenport A. P., Morton A. J., Brown M. J. Localization of endothelin-1 (ET-1), ET-2, and ET-3, mouse VIC, and sarafotoxin S6b binding sites in mammalian heart and kidney. J Cardiovasc Pharmacol. 1991;17 (Suppl 7):S152–S155. doi: 10.1097/00005344-199100177-00042. [DOI] [PubMed] [Google Scholar]
  10. Davenport A. P., Nunez D. J., Hall J. A., Kaumann A. J., Brown M. J. Autoradiographical localization of binding sites for porcine [125I]endothelin-1 in humans, pigs, and rats: functional relevance in humans. J Cardiovasc Pharmacol. 1989;13 (Suppl 5):S166–S170. doi: 10.1097/00005344-198900135-00045. [DOI] [PubMed] [Google Scholar]
  11. Davenport A. P., O'Reilly G., Kuc R. E. Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type. Br J Pharmacol. 1995 Mar;114(6):1110–1116. doi: 10.1111/j.1476-5381.1995.tb13322.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Davenport A. P., O'Reilly G., Molenaar P., Maguire J. J., Kuc R. E., Sharkey A., Bacon C. R., Ferro A. Human endothelin receptors characterized using reverse transcriptase-polymerase chain reaction, in situ hybridization, and subtype-selective ligands BQ123 and BQ3020: evidence for expression of ETB receptors in human vascular smooth muscle. J Cardiovasc Pharmacol. 1993;22 (Suppl 8):S22–S25. doi: 10.1097/00005344-199322008-00008. [DOI] [PubMed] [Google Scholar]
  13. Elshourbagy N. A., Lee J. A., Korman D. R., Nuthalaganti P., Sylvester D. R., Dilella A. G., Sutiphong J. A., Kumar C. S. Molecular cloning and characterization of the major endothelin receptor subtype in porcine cerebellum. Mol Pharmacol. 1992 Mar;41(3):465–473. [PubMed] [Google Scholar]
  14. Fujimoto M., Mihara S., Nakajima S., Ueda M., Nakamura M., Sakurai K. A novel non-peptide endothelin antagonist isolated from bayberry, Myrica cerifera. FEBS Lett. 1992 Jun 22;305(1):41–44. doi: 10.1016/0014-5793(92)80651-v. [DOI] [PubMed] [Google Scholar]
  15. Fukuroda T., Ozaki S., Ihara M., Ishikawa K., Yano M., Nishikibe M. Synergistic inhibition by BQ-123 and BQ-788 of endothelin-1-induced contractions of the rabbit pulmonary artery. Br J Pharmacol. 1994 Oct;113(2):336–338. doi: 10.1111/j.1476-5381.1994.tb16901.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Gardiner S. M., Kemp P. A., March J. E., Bennett T., Davenport A. P., Edvinsson L. Effects of an ET1-receptor antagonist, FR139317, on regional haemodynamic responses to endothelin-1 and [Ala11,15]Ac-endothelin-1 (6-21) in conscious rats. Br J Pharmacol. 1994 Jun;112(2):477–486. doi: 10.1111/j.1476-5381.1994.tb13098.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Godfraind T. Endothelin receptors in human coronary arteries. Trends Pharmacol Sci. 1994 May;15(5):136–137. doi: 10.1016/0165-6147(94)90068-x. [DOI] [PubMed] [Google Scholar]
  18. Godfraind T. Evidence for heterogeneity of endothelin receptor distribution in human coronary artery. Br J Pharmacol. 1993 Nov;110(3):1201–1205. doi: 10.1111/j.1476-5381.1993.tb13942.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Gulati A., Sharma A. C., Robbie G., Saxena P. R. Endothelin ETA receptor antagonist, BQ-123, blocks the vasoconstriction induced by sarafotoxin 6b in the heart but not in other vascular beds. Gen Pharmacol. 1995 Jan;26(1):183–193. doi: 10.1016/0306-3623(94)00152-d. [DOI] [PubMed] [Google Scholar]
  20. Hechler U., Becker A., Haendler B., Schleuning W. D. Stable expression of human endothelin receptors ETA and ETB by transfected baby hamster kidney cells. Biochem Biophys Res Commun. 1993 Aug 16;194(3):1305–1310. doi: 10.1006/bbrc.1993.1966. [DOI] [PubMed] [Google Scholar]
  21. Hemsén A., Franco-Cereceda A., Matran R., Rudehill A., Lundberg J. M. Occurrence, specific binding sites and functional effects of endothelin in human cardiopulmonary tissue. Eur J Pharmacol. 1990 Dec 4;191(3):319–328. doi: 10.1016/0014-2999(90)94164-s. [DOI] [PubMed] [Google Scholar]
  22. Howard P. G., Plumpton C., Davenport A. P. Anatomical localization and pharmacological activity of mature endothelins and their precursors in human vascular tissue. J Hypertens. 1992 Nov;10(11):1379–1386. doi: 10.1097/00004872-199211000-00010. [DOI] [PubMed] [Google Scholar]
  23. Ihara M., Noguchi K., Saeki T., Fukuroda T., Tsuchida S., Kimura S., Fukami T., Ishikawa K., Nishikibe M., Yano M. Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci. 1992;50(4):247–255. doi: 10.1016/0024-3205(92)90331-i. [DOI] [PubMed] [Google Scholar]
  24. Ihara M., Saeki T., Fukuroda T., Kimura S., Ozaki S., Patel A. C., Yano M. A novel radioligand [125I]BQ-3020 selective for endothelin (ETB) receptors. Life Sci. 1992;51(6):PL47–PL52. doi: 10.1016/0024-3205(92)90418-o. [DOI] [PubMed] [Google Scholar]
  25. Ishikawa K., Ihara M., Noguchi K., Mase T., Mino N., Saeki T., Fukuroda T., Fukami T., Ozaki S., Nagase T. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci U S A. 1994 May 24;91(11):4892–4896. doi: 10.1073/pnas.91.11.4892. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Ishikawa T., Yanagisawa M., Kimura S., Goto K., Masaki T. Positive inotropic action of novel vasoconstrictor peptide endothelin on guinea pig atria. Am J Physiol. 1988 Oct;255(4 Pt 2):H970–H973. doi: 10.1152/ajpheart.1988.255.4.H970. [DOI] [PubMed] [Google Scholar]
  27. Karet F. E., Kuc R. E., Davenport A. P. Novel ligands BQ123 and BQ3020 characterize endothelin receptor subtypes ETA and ETB in human kidney. Kidney Int. 1993 Jul;44(1):36–42. doi: 10.1038/ki.1993.210. [DOI] [PubMed] [Google Scholar]
  28. Katwa L. C., Guarda E., Weber K. T. Endothelin receptors in cultured adult rat cardiac fibroblasts. Cardiovasc Res. 1993 Dec;27(12):2125–2129. doi: 10.1093/cvr/27.12.2125. [DOI] [PubMed] [Google Scholar]
  29. Kikuchi T., Ohtaki T., Kawata A., Imada T., Asami T., Masuda Y., Sugo T., Kusumoto K., Kubo K., Watanabe T. Cyclic hexapeptide endothelin receptor antagonists highly potent for both receptor subtypes ETA and ETB. Biochem Biophys Res Commun. 1994 May 16;200(3):1708–1712. doi: 10.1006/bbrc.1994.1649. [DOI] [PubMed] [Google Scholar]
  30. Kitayoshi T., Watanabe T., Shimamoto N. Cardiovascular effects of endothelin in dogs: positive inotropic action in vivo. Eur J Pharmacol. 1989 Aug 3;166(3):519–522. doi: 10.1016/0014-2999(89)90367-1. [DOI] [PubMed] [Google Scholar]
  31. Li J. S., Larivière R., Schiffrin E. L. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy. Hypertension. 1994 Aug;24(2):183–188. doi: 10.1161/01.hyp.24.2.183. [DOI] [PubMed] [Google Scholar]
  32. Maguire J. J., Davenport A. P. ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro. Br J Pharmacol. 1995 May;115(1):191–197. doi: 10.1111/j.1476-5381.1995.tb16338.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. McPherson G. A. A practical computer-based approach to the analysis of radioligand binding experiments. Comput Programs Biomed. 1983 Aug-Oct;17(1-2):107–113. doi: 10.1016/0010-468x(83)90031-4. [DOI] [PubMed] [Google Scholar]
  34. Mihara S., Fujimoto M. The endothelin ETA receptor-specific effect of 50-235, a nonpeptide endothelin antagonist. Eur J Pharmacol. 1993 Jun 15;246(1):33–38. doi: 10.1016/0922-4106(93)90006-u. [DOI] [PubMed] [Google Scholar]
  35. Molenaar P., O'Reilly G., Sharkey A., Kuc R. E., Harding D. P., Plumpton C., Gresham G. A., Davenport A. P. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res. 1993 Mar;72(3):526–538. doi: 10.1161/01.res.72.3.526. [DOI] [PubMed] [Google Scholar]
  36. Moravec C. S., Reynolds E. E., Stewart R. W., Bond M. Endothelin is a positive inotropic agent in human and rat heart in vitro. Biochem Biophys Res Commun. 1989 Feb 28;159(1):14–18. doi: 10.1016/0006-291x(89)92397-8. [DOI] [PubMed] [Google Scholar]
  37. Munson P. J., Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 1980 Sep 1;107(1):220–239. doi: 10.1016/0003-2697(80)90515-1. [DOI] [PubMed] [Google Scholar]
  38. Nambi P., Pullen M., Spielman W. Species differences in the binding characteristics of [125I]IRL-1620, a potent agonist specific for endothelin-B receptors. J Pharmacol Exp Ther. 1994 Jan;268(1):202–207. [PubMed] [Google Scholar]
  39. Ogawa Y., Nakao K., Arai H., Nakagawa O., Hosoda K., Suga S., Nakanishi S., Imura H. Molecular cloning of a non-isopeptide-selective human endothelin receptor. Biochem Biophys Res Commun. 1991 Jul 15;178(1):248–255. doi: 10.1016/0006-291x(91)91806-n. [DOI] [PubMed] [Google Scholar]
  40. Peter M. G., Davenport A. P. Selectivity of [125I]-PD151242 for human, rat and porcine endothelin ETA receptors in the heart. Br J Pharmacol. 1995 Jan;114(2):297–302. doi: 10.1111/j.1476-5381.1995.tb13226.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Plumpton C., Champeney R., Ashby M. J., Kuc R. E., Davenport A. P. Characterization of endothelin isoforms in human heart: endothelin-2 demonstrated. J Cardiovasc Pharmacol. 1993;22 (Suppl 8):S26–S28. doi: 10.1097/00005344-199322008-00009. [DOI] [PubMed] [Google Scholar]
  42. Qiu Z., Wang J., Perreault C. L., Meuse A. J., Grossman W., Morgan J. P. Effects of endothelin on intracellular Ca2+ and contractility in single ventricular myocytes from the ferret and human. Eur J Pharmacol. 1992 Apr 22;214(2-3):293–296. doi: 10.1016/0014-2999(92)90134-p. [DOI] [PubMed] [Google Scholar]
  43. Reynolds E. E., Hwang O., Flynn M. A., Welch K. M., Cody W. L., Steinbaugh B., He J. X., Chung F. Z., Doherty A. M. Pharmacological differences between rat and human endothelin B receptors. Biochem Biophys Res Commun. 1995 Apr 17;209(2):506–512. doi: 10.1006/bbrc.1995.1530. [DOI] [PubMed] [Google Scholar]
  44. Richard V., Kaeffer N., Hogie M., Tron C., Blanc T., Thuillez C. Role of endogenous endothelin in myocardial and coronary endothelial injury after ischaemia and reperfusion in rats: studies with bosentan, a mixed ETA-ETB antagonist. Br J Pharmacol. 1994 Nov;113(3):869–876. doi: 10.1111/j.1476-5381.1994.tb17073.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Saeki T., Ihara M., Fukuroda T., Yamagiwa M., Yano M. [Ala1,3,11,15]endothelin-1 analogs with ETB agonistic activity. Biochem Biophys Res Commun. 1991 Aug 30;179(1):286–292. doi: 10.1016/0006-291x(91)91367-l. [DOI] [PubMed] [Google Scholar]
  46. Saetrum Opgaard O., Adner M., Gulbenkian S., Edvinsson L. Localization of endothelin immunoreactivity and demonstration of constrictory endothelin-A receptors in human coronary arteries and veins. J Cardiovasc Pharmacol. 1994 Apr;23(4):576–583. doi: 10.1097/00005344-199404000-00009. [DOI] [PubMed] [Google Scholar]
  47. Sakamoto A., Yanagisawa M., Sawamura T., Enoki T., Ohtani T., Sakurai T., Nakao K., Toyo-oka T., Masaki T. Distinct subdomains of human endothelin receptors determine their selectivity to endothelinA-selective antagonist and endothelinB-selective agonists. J Biol Chem. 1993 Apr 25;268(12):8547–8553. [PubMed] [Google Scholar]
  48. Teerlink J. R., Löffler B. M., Hess P., Maire J. P., Clozel M., Clozel J. P. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan). Circulation. 1994 Nov;90(5):2510–2518. doi: 10.1161/01.cir.90.5.2510. [DOI] [PubMed] [Google Scholar]
  49. Tsukahara H., Ende H., Magazine H. I., Bahou W. F., Goligorsky M. S. Molecular and functional characterization of the non-isopeptide-selective ETB receptor in endothelial cells. Receptor coupling to nitric oxide synthase. J Biol Chem. 1994 Aug 26;269(34):21778–21785. [PubMed] [Google Scholar]
  50. Urade Y., Fujitani Y., Oda K., Watakabe T., Umemura I., Takai M., Okada T., Sakata K., Karaki H. An endothelin B receptor-selective antagonist: IRL 1038, [Cys11- Cys15]-endothelin-1(11-21) FEBS Lett. 1994 Mar 28;342(1):103–103. doi: 10.1016/0014-5793(94)80593-8. [DOI] [PubMed] [Google Scholar]
  51. Urade Y., Fujitani Y., Oda K., Watakabe T., Umemura I., Takai M., Okada T., Sakata K., Karaki H. An endothelin B receptor-selective antagonist: IRL 1038, [Cys11-Cys15]-endothelin-1(11-21) FEBS Lett. 1992 Oct 12;311(1):12–16. doi: 10.1016/0014-5793(92)81355-p. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES